Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$71.91 +4.2%	$26.46	$4.77 ▼ $75.51	$5.21B	0.56	3.24 million shs	959,886 shs
HROW Harrow	$34.83 +3.2%	$32.63	$20.85 ▼ $59.23	$1.24B	0.41	464,793 shs	2.37 million shs
KRYS Krystal Biotech	$143.62 +4.4%	$142.44	$122.80 ▼ $207.84	$3.98B	0.7	426,993 shs	332,287 shs
MRUS Merus	$63.77 -1.3%	$58.25	$33.19 ▼ $67.59	$4.89B	1.09	697,373 shs	584,380 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	-1.61%	-4.26%	+734.34%	+1,042.38%	+516.62%
HROW Harrow	-2.00%	+0.96%	-3.41%	+28.44%	-6.12%
KRYS Krystal Biotech	-0.81%	+1.93%	-7.17%	+2.24%	-24.50%
MRUS Merus	+0.94%	-3.48%	+18.53%	+57.87%	+27.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX Abivax	3.7414 of 5 stars	4.6	4.0	0.0	3.3	0.8	0.6
HROW Harrow	2.5449 of 5 stars	3.5	1.0	0.0	3.0	2.5	0.6
KRYS Krystal Biotech	4.7396 of 5 stars	3.5	2.0	4.7	2.3	3.3	2.5
MRUS Merus	2.8645 of 5 stars	3.5	4.0	0.0	2.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.13	Buy	$92.33	28.40% Upside
HROW Harrow	3.00	Buy	$63.83	83.27% Upside
KRYS Krystal Biotech	3.00	Buy	$210.75	46.74% Upside
MRUS Merus	3.09	Buy	$88.50	38.78% Upside

Current Analyst Ratings Breakdown

Latest HROW, ABVX, MRUS, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	MRUS Merus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$97.00 ➝ $96.00
8/5/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$176.00 ➝ $166.00
8/5/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00
7/29/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $112.00
7/25/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
7/25/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00
7/23/2025	ABVX Abivax	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$74.00
7/23/2025	ABVX Abivax	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$45.00 ➝ $101.00
7/23/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $70.00
7/23/2025	ABVX Abivax	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $101.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
HROW Harrow	$199.61M	6.40	$0.14 per share	246.74	$1.95 per share	17.86
KRYS Krystal Biotech	$290.52M	14.31	$4.84 per share	29.66	$35.96 per share	3.99
MRUS Merus	$36.13M	133.49	N/A	N/A	$11.13 per share	5.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
HROW Harrow	-$17.48M	-$0.56	N/A	87.08	N/A	-4.49%	-2.08%	-0.34%	N/A
KRYS Krystal Biotech	$89.16M	$4.92	29.19	14.25	N/A	40.85%	15.21%	13.81%	N/A
MRUS Merus	-$215.33M	-$5.50	N/A	N/A	N/A	-685.64%	-50.28%	-42.00%	10/30/2025 (Estimated)

Latest HROW, ABVX, MRUS, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	HROW Harrow	$0.01	$0.24	+$0.23	$0.13	$64.23 million	$63.74 million
8/5/2025	Q1 2025	MRUS Merus	-$1.17	-$2.23	-$1.06	-$2.23	$9.77 million	$8.83 million
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.08	$1.29	+$0.21	$1.29	$95.42 million	$96.04 million
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	1.25	1.25
HROW Harrow	2.01	0.91	0.85
KRYS Krystal Biotech	N/A	9.68	9.33
MRUS Merus	N/A	8.39	8.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
HROW Harrow	72.76%
KRYS Krystal Biotech	86.29%
MRUS Merus	96.14%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
HROW Harrow	13.67%
KRYS Krystal Biotech	13.70%
MRUS Merus	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	75.55 million	N/A	Not Optionable
HROW Harrow	180	36.69 million	31.67 million	Optionable
KRYS Krystal Biotech	210	28.94 million	24.98 million	Optionable
MRUS Merus	37	75.63 million	72.84 million	Optionable

HROW, ABVX, MRUS, and KRYS Headlines

Recent News About These Companies

HC Wainwright Comments on Merus' Q3 Earnings (NASDAQ:MRUS)

August 12 at 2:35 AM | americanbankingnews.com

What is HC Wainwright's Estimate for Merus Q3 Earnings?

August 11 at 2:58 AM | marketbeat.com

Leerink Partnrs Comments on Merus' Q3 Earnings (NASDAQ:MRUS)

August 11 at 2:43 AM | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Receives Consensus Recommendation of "Buy" from Brokerages

August 11 at 2:30 AM | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Receives Average Rating of "Buy" from Brokerages

August 10 at 2:05 AM | americanbankingnews.com

William Blair Issues Pessimistic Outlook for Merus Earnings

August 10 at 2:31 AM | americanbankingnews.com

William Blair Issues Pessimistic Estimate for Merus Earnings

August 9 at 8:09 AM | marketbeat.com

Merus (NASDAQ:MRUS) Upgraded at HC Wainwright

August 9 at 7:46 AM | marketbeat.com

Needham & Company LLC Lowers Merus (NASDAQ:MRUS) Price Target to $96.00

August 7, 2025 | marketbeat.com

We Think Merus (NASDAQ:MRUS) Can Afford To Drive Business Growth

August 7, 2025 | finance.yahoo.com

Merus (NASDAQ:MRUS) Issues Earnings Results

August 6, 2025 | marketbeat.com

Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

August 6, 2025 | globenewswire.com

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

August 5, 2025 | zacks.com

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

August 5, 2025 | globenewswire.com

Westfield Capital Management Co. LP Acquires 508,063 Shares of Merus N.V. (NASDAQ:MRUS)

August 5, 2025 | marketbeat.com

Envestnet Asset Management Inc. Makes New $589,000 Investment in Merus N.V. (NASDAQ:MRUS)

August 5, 2025 | marketbeat.com

Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2025 | globenewswire.com

BIT Capital GmbH Increases Position in Merus N.V. (NASDAQ:MRUS)

August 4, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Stock Position Raised by Allianz Asset Management GmbH

August 3, 2025 | marketbeat.com

TD Asset Management Inc Decreases Stock Position in Merus N.V. (NASDAQ:MRUS)

August 3, 2025 | marketbeat.com

Merus (NASDAQ:MRUS) Sets New 52-Week High - Here's Why

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW, ABVX, MRUS, and KRYS Company Descriptions

Abivax NASDAQ:ABVX

$71.91 +2.91 (+4.22%)

Closing price 04:00 PM Eastern

Extended Trading

$72.04 +0.13 (+0.17%)

As of 07:38 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Harrow NASDAQ:HROW

$34.83 +1.09 (+3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$35.15 +0.32 (+0.92%)

As of 07:59 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Krystal Biotech NASDAQ:KRYS

$143.62 +6.08 (+4.42%)

Closing price 04:00 PM Eastern

Extended Trading

$143.62 +0.00 (+0.00%)

As of 07:27 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Merus NASDAQ:MRUS

$63.77 -0.83 (-1.28%)

Closing price 04:00 PM Eastern

Extended Trading

$63.72 -0.05 (-0.09%)

As of 06:08 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time